RecruitingPhase 2

Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)

United States17 participantsStarted 2025-02-01

Plain-language summary

A single-arm open-label study assessing short-term (week 6, 16) and long-term (week 32) efficacy of guselkumab in adult participants with pyoderma gangrenosum (PG)

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. 12 weeks for ustekinumab, ixekizumab, secukinumab, brodalumab;
✕. 8 weeks for infliximab;
✕. 6 weeks for adalimumab;
✕. 4 weeks for cyclosporine A, etanercept, inhibitors of the JAK/TYK pathway and PD4 inhibitors;
✕. 2 weeks for Calcineurin inhibitor topicals (including but not limited to pimecrolimus and tacrolimus) and other advanced topicals (including but not limited to roflumilast and tapinarof).

What they're measuring

Healing

Timeframe: Week 32

Trial details

NCT IDNCT06563323

SponsorOregon Health and Science University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-08-13

Contact for this trial

Alex G Ortega-Loayza, MD, MCR

503-418-3376 ortegalo@ohsu.edu

View on ClinicalTrials.gov More Pyoderma Gangrenosum trials